BEERSE, Belgium – Janssen Pharmaceutica NV, which is under the Janssen Pharmaceutical Companies umbrella, has completed divesting its animal health business to Elanco, a division of Eli Lilly and Company. Janssen Animal Health has operations in 11 countries and focuses on targeted disease segments in companion animals and livestock with special focus on pigs and poultry.

According to terms of the transaction, Elanco will acquire products, contracts and related intellectual property and marketing authorizations. Affected employees, located in 11 different countries, will transfer to Elanco to support a significantly expanded portfolio of products.